CLINICAL_TRIALS
trial_result
· 2016-01-20
Clinical Trial Update: Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2) [Phase 3]
Summary
Phase 3 OTEMTO 2 results for the tiotropium/olodaterol fixed-dose combination in chronic obstructive pulmonary disease were posted in January 2016.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2016-01-20